PARP1 promotes the progression of hepatocellular carcinoma by regulating expression of POU2F2

doi:10.19401/j.cnki.1007-3639.2024.09.005

Abstract

Abstract:

Background and purpose: Hepatocellular carcinoma (HCC) is a major disease seriously threatening human health. Poly (ADP-ribose) polymerase-1 (PARP1) is an enzyme that catalyzes poly ADP-ribosylation. Given the role of PARP1 in DNA damage repair, it is generally considered as an oncogene. However, the expression of PARP1 and its mechanism in HCC are not yet clear. This study aimed to investigate the role of PARP1 in the occurrence and development of HCC and its potential mechanisms. Methods: First, we analyzed the expression pattern of PARP1 in The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) HCC database, and identified the expression trend of PARP1 in our HCC cohort using real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) and Western blot. Then, the enzyme activity of PARP1 was inhibited by PJ34, an inhibitor of PARP1 and the expression of PARP1 in HCC cell lines was downregulated with small RNA interference technology. Based on these models, the following experiments were conducted: First, the effect of PARP1 on cell viability was assessed by cell counting kit-8 (CCK-8) assay and flow cytometry; Second, the expression levels of stemness-related genes in HCC cells were identified using RTFQ-PCR; Third, the effect of inhibition of PARP1 on migration and invasion of HCC cells was detected by migration and invasion assay (transwell assay). Finally, bioinformatic analysis was performed to identify new target genes and the pathways regulated by PARP1 in HCC progression. Rescue experiments were performed to determine whether PARP1 target genes were involved in the malignant phenotypes of HCC cells. Results: The expression of PARP1 was significantly up-regulated in HCC tissues in both TCGA and CPTAC database. RTFQ-PCR and Western blot assays showed that PARP1 was obviously up-regulated in HCC tissues compared to paracancerous tissues. Survival analysis showed that PARP1 expression was significantly negatively correlated with the prognosis of patients. The results of CCK-8, flow cytometry, RTFQ-PCR and transwell assay indicated that inhibition of PARP1 attenuated proliferation and activity of HCC cells, as well as weakened their stemness, migration and invasion. Bioinformatics analysis suggested that PARP1-regulated genes were enriched in the nuclear factor-κB (NF-κB) and necroptosis pathways, with POU class homeobox 2 (POU2F2) potentially being a target gene of PARP1. Correlation analysis, along with RTFQ-PCR and Western blot detection, confirmed that the expression of POU2F2 was regulated by PARP1, while not affected by PJ34, indicating the effect of nonenzymatic function of PARP1 on POU2F2. CCK-8, flow cytometry and RTFQ-PCR results showed that the reintroduction of POU2F2 enhanced proliferative capacity, increased activity, and promoted stemness of HCC cell lines with PARP1 knockdown. Conclusion: By positively regulating the expression of POU2F2, PARP1 promotes malignant phenotypes of HCC cells, providing new insights for clinical treatment and drug development for HCC.

Key words: Hepatocellular carcinoma, Poly (ADP-ribose) polymerase 1, POU class homeobox 2, Proliferation, Activity, Stemness

CLC Number:

R735.7

WEN Ziqiang, LAN Junliang, ZHOU Bo, XU Qiwei. PARP1 promotes the progression of hepatocellular carcinoma by regulating expression of POU2F2[J]. China Oncology, 2024, 34(9): 848-856.

Figures/Tables 5

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

References 12

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	MO Z Q, LV L, MAI Q C, et al. Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy[J]. J Immunother Cancer, 2024, 12(1): e008191.
[3]	GUO C L, ZHANG F, WU X C, et al. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo[J]. Int J Biol Macromol, 2020, 150: 238-245.
[4]	HUANG S H, XIONG M, CHEN X P, et al. PJ34, an inhibitor of PARP1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells[J]. Oncol Rep, 2008, 20(3): 567-572.
[5]	ZHU H, CHEN K, CHEN Y L, et al. RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis[J]. Signal Transduct Target Ther, 2022, 7(1): 240.
[6]	IM J Y, KANG M J, KIM B K, et al. DDIAS, DNA damage-induced apoptosis suppressor, is a potential therapeutic target in cancer[J]. Exp Mol Med, 2023, 55(5): 879-885.
[7]	YANG X D, KONG F N, QI L, et al. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma[J]. Mol Cancer, 2021, 20(1): 20.
[8]	MELIKISHVILI M, CHARIKER J H, ROUCHKA E C, et al. Transcriptome-wide identification of the RNA-binding landscape of the chromatin-associated protein PARP1 reveals functions in RNA biogenesis[J]. Cell Discov, 2017, 3: 17043. doi: 10.1038/celldisc.2017.43 pmid: 29387452
[9]	VUONG B, HOGAN-CANN A D J, ALANO C C, et al. NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1[J]. J Neuroinflammation, 2015, 12: 229.
[10]	CHERNG Y G, CHU Y C, YADAV V K, et al. Induced mitochondrial alteration and DNA damage via IFNGR-JAK2-STAT1-PARP1 pathway facilitates viral hepatitis associated hepatocellular carcinoma aggressiveness and stemness[J]. Cancers, 2021, 13(11): 2755.
[11]	MALONE C S, PATRONE L, BUCHANAN K L, et al. An upstream Oct-1- and Oct-2-binding silencer governs B29 (Ig beta) gene expression[J]. J Immunol, 2000, 164(5): 2550-2556. pmid: 10679093
[12]	YUAN C W, PANG L J, WANG W J, et al. POU2F2-IL-31 autoregulatory circuit converts hepatocytes into the origin cells of hepatocellular carcinoma[J]. Adv Sci, 2021, 8(13): e2004683.

[1]	XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan. Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma [J]. China Oncology, 2024, 34(8): 726-733.
[2]	CAO Fei, YU Wenhao, TANG Xiaonan, MA Zidong, CHANG Tingmin, GONG Yabin, LIAO Mingjuan, KANG Xiaohong. Mechanism of LINC01410 promoting proliferation and migration in esophageal squamous cell carcinoma [J]. China Oncology, 2024, 34(8): 753-762.
[3]	CHEN Xun, ZHENG Zhenxia, RUAN Xueru. Effects of TMCO1 on proliferation and migration of cervical cancer cells [J]. China Oncology, 2024, 34(6): 571-580.
[4]	SUN Rongqi, SONG Ning, ZHENG Wentian, ZHANG Xinyue, LI Minmin, GONG Hui, JIANG Yingying. Effect of long noncoding RNA FLJ30679 on proliferation and migration of oral squamous cell carcinoma cells [J]. China Oncology, 2024, 34(5): 439-450.
[5]	XIONG Jiayan, LEI Wei, YOU Bo, ZHANG Zhenxin, XIE Haijing, SHAN Ying, XIA Tian, ZHOU Yong. Study on the mechanism of DDX6 promoting proliferation and migration of nasopharyngeal carcinoma cells by regulating stability of CKMT1A mRNA [J]. China Oncology, 2024, 34(5): 451-459.
[6]	ZHOU Xueqin, LUAN Yanchao, ZHAO Li, RONG Chaochao, YANG Na. Expression of CDC20 in lung adenocarcinoma tissues and its effect on the proliferation and invasion of lung adenocarcinoma cells [J]. China Oncology, 2024, 34(5): 460-472.
[7]	GUAN Ruirui, HAO Qian, ZHANG Yaqi, SUN Qinggang, CHEN Yitian, LI Xiumin, ZHOU Xiang, HAN Tao. CDC20 facilitates the proliferation of esophageal carcinoma cell by stabilizing NLRP3 expression [J]. China Oncology, 2024, 34(5): 473-484.
[8]	WANG Xuemei, CHENG Yu, QI Jiemin. PRMT7 inhibits proliferation and migration of bladder cancer cells by regulating Notch signaling pathway [J]. China Oncology, 2023, 33(5): 437-444.
[9]	ZHANG Pingchuan, DU Mingyu, YAO Chengyun, HE Xia, YIN Li. Mechanism of circular RNA hsa_circ_0012779 expression in nasopharyngeal carcinoma and its influence on cell biological behavior [J]. China Oncology, 2023, 33(5): 445-451.
[10]	ZHAO Haichao, GAO Qiang. Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 [J]. China Oncology, 2023, 33(4): 315-326.
[11]	XIAO Lanshu, PAN Liudi, LIU Yi, WANG Jie, CHEN Hui. LncRNA DLEU7-AS1 contributes to proliferation and migration of gastric cancer by regulating MSN transcription [J]. China Oncology, 2023, 33(4): 327-341.
[12]	CHEN Hong, CHEN Junxia. Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(4): 342-353.
[13]	PENG Jin, WANG Weining, TAN Zhi, YE Guannan, ZHOU Zhen. The mechanism of m6Am-modifying enzyme PCIF1 regulating target gene ACOT8 in gastric cancer progression [J]. China Oncology, 2023, 33(4): 368-376.
[14]	FU Qingsheng, JIN Lei, ZHANG Xudong, XU Yingchen, ZHU Chunfu, QIN Xihu, WU Baoqiang. Effect of tRF-Pro-CGG on the biological behavior of mouse pancreatic cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(3): 241-249.
[15]	HU Keshu, LIU Wenfeng, ZHANG Feng, QUAN Bing, YIN Xin. Mechanism of LINC00601 in regulating sensitivity of hepatocellular carcinoma cells to oxaliplatin chemotherapy [J]. China Oncology, 2023, 33(1): 25-35.